{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=US+Licensed+Vaccine",
    "query": {
      "intervention": "US Licensed Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=US+Licensed+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T23:39:06.049Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03207750",
      "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rotavirus Infection",
        "Rotavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1280,
      "start_date": "2017-09-14",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207750"
    },
    {
      "nct_id": "NCT02212106",
      "title": "A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator Quadrivalent Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "5 Years to 8 Years"
      },
      "enrollment_count": 402,
      "start_date": "2014-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2015-10-16",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Binghamton",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02212106"
    },
    {
      "nct_id": "NCT01482052",
      "title": "Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Meningococcal Meningitis",
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "meningococcal meningitis conjugate vaccine, quadrivalent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "JN-International Medical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 1,
      "location_summary": "Hanford, California",
      "locations": [
        {
          "city": "Hanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01482052"
    },
    {
      "nct_id": "NCT00693706",
      "title": "Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Trivalent influenza vaccine GSK 138842A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 200,
      "start_date": "2008-06-02",
      "completion_date": "2009-03-26",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693706"
    },
    {
      "nct_id": "NCT02872311",
      "title": "Open-Label Influenza Vaccine Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immune Response"
      ],
      "interventions": [
        {
          "name": "High Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Adjuvanted Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Marshfield Clinic Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "65 Years to 74 Years"
      },
      "enrollment_count": 179,
      "start_date": "2016-09",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 1,
      "location_summary": "Marshfield, Wisconsin",
      "locations": [
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02872311"
    },
    {
      "nct_id": "NCT00735475",
      "title": "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "CSL Limited Influenza Virus Vaccine (Afluria®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "US Licensed Influenza Virus Vaccine (Fluzone®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1268,
      "start_date": "2008-10",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 13,
      "location_summary": "Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more",
      "locations": [
        {
          "city": "Mountain Home",
          "state": "Arkansas"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735475"
    },
    {
      "nct_id": "NCT00109330",
      "title": "A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Acellular Pertussis"
      ],
      "interventions": [
        {
          "name": "Combined diphtheria, tetanus, acellular pertussis vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 4116,
      "start_date": "2002-11",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 44,
      "location_summary": "Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 39 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109330"
    },
    {
      "nct_id": "NCT00264576",
      "title": "Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Disease; Flu"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 613,
      "start_date": "2005-10",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 4,
      "location_summary": "Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00264576"
    },
    {
      "nct_id": "NCT02545543",
      "title": "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Seqirus QIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Comparator QIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 2278,
      "start_date": "2015-09",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Madera, California • Ontario, California + 29 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Ontario",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02545543"
    },
    {
      "nct_id": "NCT06501963",
      "title": "Revealing Protective Immunity to Influenza Using Systems Immunology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Live Attenuated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 51,
      "start_date": "2024-10-14",
      "completion_date": "2025-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-28T23:39:06.049Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06501963"
    }
  ]
}